476 related articles for article (PubMed ID: 24685132)
1. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
Sun C; Hobor S; Bertotti A; Zecchin D; Huang S; Galimi F; Cottino F; Prahallad A; Grernrum W; Tzani A; Schlicker A; Wessels LF; Smit EF; Thunnissen E; Halonen P; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Trusolino L; Bernards R
Cell Rep; 2014 Apr; 7(1):86-93. PubMed ID: 24685132
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
5. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
6. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
8. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Schoumacher M; Hurov KE; Lehár J; Yan-Neale Y; Mishina Y; Sonkin D; Korn JM; Flemming D; Jones MD; Antonakos B; Cooke VG; Steiger J; Ledell J; Stump MD; Sellers WR; Danial NN; Shao W
Cancer Res; 2014 Jun; 74(12):3294-305. PubMed ID: 24747911
[TBL] [Abstract][Full Text] [Related]
10. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
12. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
13. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
14. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
15. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
16. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
Van Schaeybroeck S; Kalimutho M; Dunne PD; Carson R; Allen W; Jithesh PV; Redmond KL; Sasazuki T; Shirasawa S; Blayney J; Michieli P; Fenning C; Lenz HJ; Lawler M; Longley DB; Johnston PG
Cell Rep; 2014 Jun; 7(6):1940-55. PubMed ID: 24931611
[TBL] [Abstract][Full Text] [Related]
17. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
Okumura S; Jänne PA
Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
20. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]